Frequent TP53 gene alterations (mutation, allelic loss, nuclear accumulation) in primary non-small cell lung cancer

European Journal of Cancer

Volumn 32, Issue 2, 1996, Pages 335-341

  Shipman, R ^a,b   Schraml, P ^a   Colombi, M ^a   Raefle, G ^a   Dalquen, P ^a   Ludwig, C ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b ZLF   (Switzerland)

Author keywords

D17S30 allelic loss; Non small cell lung cancer; p53 accumulation; p53 mutations

Indexed keywords

ARTICLE; CARCINOGENESIS; DNA SEQUENCE; GENE EXPRESSION; GENETIC POLYMORPHISM; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LUNG CANCER; METASTASIS; MUTATION; PRIORITY JOURNAL; SOUTHERN BLOTTING; TUMOR SUPPRESSOR GENE;

ALLELES; BASE SEQUENCE; CARCINOMA, NON-SMALL-CELL LUNG; CHROMOSOME DELETION; GENES, P53; HUMANS; LUNG NEOPLASMS; MOLECULAR SEQUENCE DATA; NEOPLASM PROTEINS; POINT MUTATION; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0029922421     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/0959-8049(95)00535-8     Document Type: Article

References (52)

1. Minna J, Pass H, Glatstein E, Ihde D. In DeVita, Hellman, Rosenberg, eds. Cancer: Principles and Practice of Oncology. Philadelphia, JB Lippincott, 1989, 591-705.
2. Mountain CF. Biologic, physiologic and technical determinants in surgical therapy for lung cancer. In Strauss, ed. Lung Cancer: Clinical Diagnosis and Treatment. New York, Grune and Stratton, 1983, 245-260.
3. Levine AJ, Momand J, Finlay CA. The p53 tumour suppressor gene. Nature 1991, 351, 453-456.
4. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991, 253, 49-53.
5. Caron de Fromentel C, Soussi T. TP53 tumour suppressor gene: a model for investigating human mutagenesis. Genes Chrom Cancer 1992, 4, 1-15.
6. Gazzeri S, Brambilla E, Caron de Fromental C, et al. p53 genetic abnormalities and myc activation in human lung carcinoma. Int J Cancer 1994, 58, 24-32.
7. Mitsudomi T, Steinberg SM, Nau MM, et al. p53 gene mutations in non-small cell lung cancer cell lines and their correlation with the presence of ras mutations and clinical features. Oncogene 1992, 7, 171-180.
8. Xu H-J, Quinlan DC, Davidson AG, et al. Altered retinoblastoma protein expression and prognosis in early stage non-small cell lung carcinoma. J Natl Cancer Inst 1994, 86, 695-699.
9. Fearon ER. Genetic alterations underlying colorectal tumorigenesis. Cancer Surv 1992, 12, 119-136.
10. Ito T, Seyama T, Mizuno T, et al. Unique association of p53 mutations with undifferentiated but not with differentiated carcinomas of the thyroid gland. Cancer Res 1992, 52, 1369-1371.
11. Mazars R, Pujol P, Maudelonde T, Jeanteur P, Theillet C. p53 mutations in ovarian cancer: a late event? Oncogene 1991, 6, 1685-1690.
12. von Deimling A, Eibl RH, Ohgaki H, et al. p53 mutations are associated with 17p allelic loss in grade II and grade III astrocytoma. Cancer Res 1992, 52, 2987-2990.
13. Ohgaki H, Kleiheus P, Heitz PU. p53 mutations in sporadic adrenocortical tumors. Int J Cancer 1993, 54, 408-410.
14. Bennett WP, Hollstein MC, Metcalf RA, et al. p53 mutation and protein accumulation during multistage human esophageal carcinogenesis. Cancer Res 1992, 52, 6092-6097.
15. Davidoff AM, Kerns BJM, Iglehart JD, Marks JR. Maintenance of p53 alterations throughout breast cancer progression. Cancer Res 1991, 51, 2605-2610.
16. Chiba I, Takahashi T, Nau MM, et al. Mutations in the p53 gene are frequent in primary, resected non-small cell lung cancer. Oncogene 1990, 5, 1603-1610.
17. Kishimoto Y, Murakami Y, Shiraishi M, Hayashi K, Sekiya T. Aberrations of the p53 tumor suppressor gene in human non-small cell lung carcinomas of the lung. Cancer Res 1992, 52, 4799-4804.
18. Marchetti A, Buttitta F, Merlo G, et al. p53 alterations in non-small cell lung cancers with metastatic involvement of hilar and mediastinal lymph nodes. Cancer Res 1993, 53, 2846-2851.
19. McLaren R, Zuzu I, Dunhill M, Harris A, Lane D, Gatter KC. The relationship of p53 immunostaining to survival in carcinoma of the lung. Br J Cancer 1992, 66, 735-738.
20. Brambilla E, Gazzeri S, Moro D, et al. Immunohistochemical study of p53 in human lung carcinomas. Am J Pathol 1993, 143, 199-210.
21. Westra W, Offerhaus J, Goodman S, et al. Overexpression of the p53 tumor suppressor gene product in primary lung adenocarcinomas is associated with cigarette smoking. Am J Surg Pathol 1993, 17, 213-220.
22. Brambilla E, Moro D, Veale D, et al. Basal cell (basaloid) carcinoma of the lung. Human Pathol 1993, 23, 993-1003.
23. Quinlan D, Davidson AG, Summers CL, Warden HE, Doshi HM. Accumulation of p53 protein correlates with a poor prognosis in human lung cancer. Cancer Res 1992, 52, 4828-4831.
24. Bennett WP, Colby TV, Travis WD, et al. p53 protein accumulates frequently in early bronchial neoplasia. Cancer Res 1993, 53, 4817-4822.
25. Nuorva K, Soini Y, Kamel D, et al. Concurrent p53 expression in bronchial dysplasias and squamous cell lung carcinomas. Am J Pathol 1993, 142, 725-732.
26. Zheng J, Shu Q, Li Z-H, Tsao J-I, Weiss LM, Shibata D. Patterns of p53 mutations in squamous cell carcinoma of the lung. Acquisition at a relatively early age. Am J Pathol 1994, 145, 1444-1449.
27. Davis LG, Dibner MD, Battey JF. DNA preparation from cultured cells and tissue. In Basic Methods in Molecular Biology. New York, Elsevier, 1986, 47-50.
28. Church GM, Gilbert W. Genomic sequencing. Proc Natl Acad Sci USA 1984, 81, 1991-1995.
29. Nakamura Y, Ballard L, Leppert M. Isolation and mapping of a polymorphic DNA sequence pYNZ22 on chromosome 17p (D17S30). Nucleic Acids Res 1988, 16, 5707.
30. Batanian JR, Ledbetter SA, Wolff RK, et al. Rapid diagnosis of Miller-Dieker syndrome and isolated lissencephaly sequence by the polymerase chain reaction. Hum Genet 1990, 85, 555-559.
31. Baker SJ, Preisinger AC, Jessup JM, et al. p53 gene mutations occur in combination with 17p allelic deletions as late events in colorectal tumorigenesis. Cancer Res 1990, 50, 7717-7722.
32. Breukel C, Wijnen J, Tops C, wd-Klift H, Dauwerse H, Khan PM. Vector-Alu PCR: a rapid step in mapping cosmids and YACs. Nucleic Acids Res 1990, 18, 3097.
33. Orita M, Suzuki Y, Sekiya T, Hayashi K. Rapid and sensitive detection of point mutations and DNA polymorphisms using the polymerase chain reaction. Genomics 1989, 5, 874-879.
34. Ziegler A, Jonason AS, Lefell DJ, et al. Sunburn and p53 in the onset of skin cancer. Nature 1994, 372, 773-776.
35. Cordon-Cardo C, Dalbagni G, Saez GT, et al. p53 mutations in human bladder cancer: genotypic versus phenotypic patterns. Int J Cancer 1994, 56, 347-353.
36. Coles C, Thompson AM, Elder PA, et al. Evidence implicating at least two genes on chromosome 17p in breast carcinogenesis. Lancet 1990, 336, 761-763.
37. Chen P, Ellmore N, Weissman B. Functional evidence for a second tumor suppressor gene on chromosome 17. Mol Cell Biol 1994, 14, 534-542.
38. Vogelstein B, Kinzler KW. p53 function and dysfunction. Cell 1992, 70, 523-526.
39. Bodner SM, Minna JD, Jensen SM, et al. Expression of mutant p53 proteins in lung cancer correlates with the class of p53 gene mutation. Oncogene 1992, 7, 743-749.
40. Frebourg T, Barbier N, Yan Y-X, et al. Germ-line p53 mutations in 15 families with Li-Fraumeni syndrome. Am J Hum Genet 1995, 56, 608-615.
41. Lavigueur A, Maltby V, Mock D, Rossant J, Pawson T, Bernstein A. High incidence of lung, bone and lymphoid tumours in transgenic mice overexpressing mutant alleles of the p53 oncogene. Mol Cell Biol 1989, 9, 3982-3991.
42. Weston A, Willey JC, Modali R, et al. Differential DNA sequence deletions from chromosomes 3, 11, 13 and 17 in squamous cell carcinoma, large cell carcinoma and adenocarcinoma of the human lung. Proc Natl Acad Sci USA 1989, 86, 5099-5103.
43. Yokota J, Wada M, Shimosato Y, Terada M, Sugimura T. Loss of heterozygosity on chromosomes 3, 13 and 17 in small cell lung cancer and on chromosome 3 in adenocarcinoma of the lung. Proc Natl Acad Sci USA 1987, 84, 9252-9256.
44. Ahomadegbe JC, Barrois M, Fogel S, et al. High incidence of p53 alterations (mutation, deletion, overexpression) in head and neck primary tumors and metastases; absence of correlation with clinical outcome. Frequent protein overexpression in normal epithelium and in early non-invasive lesions. Oncogene 1995, 10, 1217-1227.
45. Slingerland JM, Jenkins JR, Benchimol S. The transforming and suppressor functions of p53 alleles: effects of mutations that disrupt phosphorylation, oligomerisation and nuclear translocation. EMBO J 1993, 12, 1029-1037.
46. Chen JY, Funk WD, Wright WE, Shay JW, Minna JD. Heterogeneity of transcriptional activity of mutant p53 protein and p53 target sequences. Oncogene 1993, 8, 2159-2166.
47. Dittmer D, Sibani P, Zambetti G. Gain of function mutations in p53. Nature Genetics 1993, 4, 42-45.
48. Lehman TA, Bennett WP, Metcalf RA, et al. p53 mutations, ras mutations, and p53-heat shock 70 protein complexes in human lung carcinoma cell lines. Cancer Res 1991, 51, 4090-4096.
49. Shaulsky G, Ben-Zeev A, Rotter V. Subcellular distribution of the p53 protein during the cell cycle of Balb/c 3T3 cells. Oncogene 1990, 5, 1707-1711.
50. Gusterson BA, Anbazhagan R, Warren W, et al. Expression of p53 in pre-malignant and malignant squamous epithelium. Oncogene 1991, 6, 1785-1789.
51. Somers KD, Merrick MA, Lopez ME, Incognito LS, Schlechter GL, Casey G. Frequent p53 mutations in head and neck cancer. Cancer Res 1992, 52, 5997-6000.
52. Passlick B, Izbicki JR, Riethmuller G, Pantel K. p53 in non-small cell lung cancer. J Natl Cancer Inst 1994, 86, 801-803.